Aridis Pharmaceuticals, Inc.
ARDS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ARDS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Sep 30, 2023.
Tracking 3 clinical trials for Aridis Pharmaceuticals, Inc..
Run Aridis Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aridis Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
4.9 months
OCF -$983K · Net income -$83K
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 6.8%
- Days to cover
- 0.2
- Shares short
- 2,003,965
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARDS short interestGovernance
Frequently asked questions
Who is the CEO of Aridis Pharmaceuticals, Inc.?
Dr. Vu L. Truong Ph.D. is the chief executive officer of Aridis Pharmaceuticals, Inc. (ARDS).
Where is Aridis Pharmaceuticals, Inc. headquartered?
Aridis Pharmaceuticals, Inc. (ARDS) is headquartered in Los Gatos, CA, United States.
What therapeutic areas does Aridis Pharmaceuticals, Inc. focus on?
Aridis Pharmaceuticals, Inc. develops therapies across Oncology, Rare Disease, Infectious Disease, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.